PanOptica raises $45m to finance clinical development of anti-VEGF eye drop for wet AMD - 1 views
-
Alex Parker on 16 Apr 14PanOptica has raised up to $45m in a Series B financing to fund the clinical program for its lead compound, PAN-90806, a pharmacologically unique small-molecule selective inhibitor of VEGF